French AI startup Mistral has raised $830 million in debt financing to build a new Nvidia-powered data center near Paris, set to open in Q2 2026.

KubeCon Europe 2026 spotlighted AI inference as its central theme, with CNCF receiving major donations including Nvidia's GPU DRA driver and the llm-d project.

Nvidia CEO Jensen Huang states I think we have achieved AGI on Lex Fridman podcast, sparking debate about the vaguely defined term. Huang references OpenClaw viral success as evidence of AI agent capabilities.

Meta revealed four new Broadcom-built MTIA chips (300–500 series) for AI inference, claiming some exceed leading commercial silicon, with a six-month release cadence targeting gigawatt-scale deployment.

NVIDIA announced a strategic $2 billion investment in AI cloud provider Nebius Group, partnering to develop hyperscale AI factories and deploy over 5 gigawatts of NVIDIA computing capacity by 2030 to meet surging global AI demand.

Nvidia disclosed a $26 billion plan to build open-weight AI models, directly challenging OpenAI and Anthropic, while simultaneously launching Nemotron 3 Super — a 120B-parameter open model delivering 5x higher throughput for agentic AI systems.

Nvidia reported record fiscal Q4 2026 revenue of $68.1B, up 73% year-over-year, with data center revenue surging 75% to $62.3B and Q1 guidance of $78B beating analyst expectations.

Amazon's Trainium and Google's TPUs are gaining traction, generating billions in revenue and providing a viable alternative to Nvidia's chips for major AI players like Anthropic.

Nvidia CEO Jensen Huang confirms a significant investment in OpenAI's latest funding round, calling it potentially the largest ever, and refutes rumors of dissatisfaction.

Nvidia CEO Jensen Huang plans a strategic visit to China to address declining AI chip sales and navigate complex U.S. export regulations ahead of the Lunar New Year.

NVIDIA and Eli Lilly have announced a landmark $1 billion partnership to create a co-innovation lab focused on using AI to revolutionize drug discovery and pharmaceutical manufacturing, aiming to drastically reduce development timelines.